Return to Home
PageDisclaimer: Individual results vary. Anti-TNF treatment
for the indications below is off-label.
Please see the Legal Disclaimer. Adverse
reactions may occur. Some patients do not respond. Maintenance
dosing, usually weekly, but sometimes as little as monthly, is
necessary for optimal effect. The methods of anti-TNF treatment
utilized for these patients are patented inventions of the INR**.Please
click directly on the Flash® videos below to view their contents
within this webpage. Hint: if your internet connection is slow,
please place the video on pause and allow it to download before
playing for best playback quality. If you still have trouble viewing
the video correctly, then please visit the INR
Videos webpage with smaller version videosVideo 1: Rapid improvement within minutes and
sustained improvement through five weeks following perispinal
etanercept in Alzheimer's disease*
This video is actual
patient footage showing the patient's clinical improvement within
minutes following initiation of perispinal etanercept at the INR,
and his sustained response through five weeks. This video is a
companion to the published editorial entitled Perispinal etanercept:
potential as an Alzheimer therapeutic. Griffin WS. Journal
of Neuroinflammation 2008 January; 5:3.Video
2: Rapid cognitive improvement in Alzheimer's disease within minutes
following perispinal etanercept administration*
This video is an interview
with two family members discussing their family member's clinical
response to initiation of perispinal etanercept at the INR. For
the published results please see Rapid cognitive improvement
in Alzheimer's disease following perispinal etanercept administration.
Tobinick E, Gross H. Journal of Neuroinflammation 2008
January; 5:2. This video was included as part of the peer-reviewed,
published, scientific article.Video
3: Anti-TNF for Alzheimer's Disease, rapid and significant clinical
improvement*
This video is an interview
with a family member discussing his family member's clinical response
to initiation of perispinal etanercept at the INR. For the published
results please see TNF-alpha Modulation for Treatment of
Alzheimer's Disease: A 6-Month Pilot Study. Tobinick E,
Gross H, Weinberger A, Cohen H. MedGenMed 2006; 8(2) :25
.Video 4: Rapid improvement
in speech following anti-TNF initiation at the INR*
Rapid improvement in speech
in primary progressive aphasia following perispinal etanercept.
For the published results please see Perispinal etanercept
produces rapid improvement in primary progressive aphasia: identification
of a novel, rapidly reversible TNF-mediated pathophysiologic mechanisms.
Tobinick E. Medscape Journal of Medicine, Neurology
and Neurosurgery Clinical Cases 2008 June 10; 10(6):135. This
video was included as part of the peer-reviewed, published, scientific
article.Video 5: Anti-TNF for
Alzheimer's Disease produces rapid improvement*
This video is an interview
with a family member discussing her family member's clinical response
to initiation of perispinal etanercept at the INR. For the published
results please see TNF-alpha Modulation for Treatment of
Alzheimer's Disease: A 6-Month Pilot Study. Tobinick E,
Gross H, Weinberger A, Cohen H. MedGenMed 2006; 8(2) :25
.Downloadable
videos: These versions are in a different format from the Flash®
videos above, and can be downloaded for viewing. Please click
on the type of video which your computer is capable of viewing,
and you will be brought to the INR webpage containing that video
format. To insure optimal quality, all videos below require a
wait for download or streaming.Video 1: TNF-alpha modulation for Alzheimer's Disease
video length 3+ minutes*
(Note: This video requires
Windows Media Player, available at www.microsoft.com/windows/windowsmedia/download/).The videos above, available in different
media formats, are interviews with family members discussing their
family member's clinical response to initiation of anti-TNF treatment
at the INR. For the published results please see TNF-alpha
Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot
Study. Tobinick E, Gross H, Weinberger A, Cohen H. MedGenMed
2006; 8(2) :25 .Institute
for Neurological Research, a private medical group, inc.
100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California
90095
Return to Home
Page